CAS:850140-72-6 afatinib CAS NO.850140-72-6

Min.Order Quantity:: 1 Kilogram

Purity:: 99.5%

Port:: all chinese port

Payment Terms:: T/T,MoneyGram,Other

Add to Inquiry Cart

Product Details

Keywords

afatinib
afatinib
C24H25ClFN5O3

Quick Details

ProName: CAS:850140-72-6 afatinib
CasNo: 850140-72-6
Molecular Formula: C24H25ClFN5O3
Appearance: White powder
Application: Pharmaceuticals
DeliveryTime: within 3-4days after received your pay...
PackAge: according to customers' requirements
Port: all chinese port
ProductionCapacity: 100 Kilogram/Month
Purity: 99.5%
Storage: store in cool and dry
Transportation: by sea or by air
LimitNum: 1 Kilogram

Superiority

afatinib

afatinib brief description

cas no.:850140-72-6

mf:c24h25clfn5o3

mw:485.9384032

competitive price with high quality

conforms to bp/usp/ep/fcc

afatinib coa

item	standard	results
appearance	off-white powder	off-white powder
identification	hplc ,nmr	complies
residue on ignition	≤0.10%	0.05%
loss on drying	≤0.50%	0.15%
heavy metal	≤20ppm	<20ppm
purity(hplc)	≥99.0%	99.99%
conclusion	it complies with enterprise standard

medical use

afatit has received regulatory approval for use as a treatment for non-small cell lung cancer,although there is emerging evidence to support its use in other cancers such as breast cancer.

in october 2010 a phase iii trial in nsclc patients called lux-lung 5 began with this drug.fall 2010 interim results suggested the drug extended progression-free survival threefold compared to placebo, but did not extend overall survival.in may 2012, the phase iib/iii trial lux-lung 1 came to the same conclusion.

in january 2015 a phase iii trial in people with nsclc suggested the drug extended life expactancy in stage iv nsclc adenocarcinoma with egfr mutation type del 19-positive tumors, compared to cisplatin-based chemotherapy by a year (33 months vs. 21 months).

phase ii results for breast cancer that over-expresses the protein human epidermal growth factor receptor 2 (her2-positive breast cancer) were described as promising by the authors, with 19 of 41 patients achieving benefit from afatinib.[9] double-blind phase iii trials are under way to confirm or refute this finding. her2-negative breast cancers showed limited or no response to the drug.

Details

kono chem co.,ltd is a leading producer of standardized herbal extracts, natural active ingredients and apis for pharmaceutical, health food and cosmetic industries.

the botanical raw materials are subject to strict selection and inspection, and extracts are manufactured according to methods developed by pioneer. they include inspections to guarantee a high quality standard from both analytico-chemical and therapeutic points of view, and take into consideration the state of art in different fields: research and development, analyses, processes and machinery, therapeutic applications on a scientific basis.

with our phytopharmaceutical background and knowledge through experience, pioneer can also provide a wide range of analytical services and reference substances to our clients. in addition, we also manufacture pharmaceutical raw materials of nucleotide species, mainly including as below: sam-e tosylate disulfate; sam-e 1,4-butanedisulfonate; polycytidylic acid; polyinosinic acid; adenosine triphosphate disodium; and cytidine triphosphate disodium; these items are our strongest advantage in china. meanwhile, we can do custom made pharmaceutical ingredients depending on our professional experts in the pharmaceutical and chemistry industry.

recently, kono chem has been working hard on the research and development of new cardiovascular and anesthesia drugs, we have got good achievements; moreover, we also offer natural anticancer drugs and other pharmaceutical intermediates. as a gmp standardized manufacturer, our products can meet or even exceed the standards of cp2010, usp32, bp2005 and ep4. presently, 80% and above of our products have been well-recognized in dozens of countries and regions, such as usa, eu, south america and southeast asia. there are experienced technicians working for our institutes now, all of them are skilled. pioneer is looking forward to cooperating with friends all over the world for getting collaborative development; we are willing to work with you to develop new drugs and expand new business, let's work together for bright future.